Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Obtain formulation and manufacturing information
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

US Department of Justice
Moodys
Fuji
Covington
Deloitte
Colorcon
Dow
Cipla
Johnson and Johnson
QuintilesIMS

Generated: January 17, 2018

DrugPatentWatch Database Preview

Details for Patent: 5,910,319

« Back to Dashboard

Which drugs does patent 5,910,319 protect, and when does it expire?

Patent 5,910,319 protects PROZAC WEEKLY and is included in one NDA.

Protection for PROZAC WEEKLY has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has fifty-eight patent family members in forty-five countries.
Summary for Patent: 5,910,319
Title: Fluoxetine enteric pellets and methods for their preparation and use
Abstract:A superior enteric formulation of the antidepressant drug, fluoxetine, is in the form of enteric pellets of which the enteric layer comprises hydroxypropylmethylcellulose acetate succinate.
Inventor(s): Anderson; Neil R. (West Lafayette, IN), Harrison; Roger G. (Zionsville, IN), Lynch; Daniel F. (Indanapolis, IN), Oren; Peter L. (Fishers, IN)
Assignee: Eli Lilly and Company (Indianapolis, IN)
Application Number:08/867,196
Patent Claim Types:
see list of patent claims
Composition; Compound; Process; Device; Formulation; Dosage form; Use;

Drugs Protected by US Patent 5,910,319

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Lilly PROZAC WEEKLY fluoxetine hydrochloride CAPSULE, DELAYED REL PELLETS;ORAL 021235-001 Feb 26, 2001 AB RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 5,910,319

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
5,985,322 Method for the treatment of CNS disorders ➤ Subscribe
RE39030 Fluoxetine enteric pellets and methods for their preparation and use ➤ Subscribe
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 5,910,319

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Canada 2234826 ➤ Subscribe
Switzerland 693018 ➤ Subscribe
China 1200924 ➤ Subscribe
China 1161109 ➤ Subscribe
China 1285189 ➤ Subscribe
China 1212834 ➤ Subscribe
Austria A93198 ➤ Subscribe
Colombia 4940407 ➤ Subscribe
Czech Republic 9801143 ➤ Subscribe
Germany 19823940 ➤ Subscribe
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Novartis
Boehringer Ingelheim
Julphar
McKinsey
Chinese Patent Office
Argus Health
Deloitte
Merck
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot